
Zuellig Pharma Launches "Obesity is a Disease" Seminar as Part of "Reduce Size, Reduce Disease" Campaign
BANGKOK, July 8, 2025 /PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions provider in Asia, is organizing the "Obesity is a Disease" seminar as part of its "Reduce Size, Reduce Disease" awareness campaign. The seminar aims to reinforce the message that obesity is more than a cosmetic concern, and solutions to manage the disease among healthcare practitioners. It is a silent national public health crisis that significantly impacts individuals living with obesity, particularly women.
Studies have highlighted the urgency of addressing rising obesity rates, as the 2014 National Health Examination Survey found that 37.5% of Thais aged 15 and over were obese (BMI > 25), with the rate for women at 41.8%. By 2023, this figure had climbed to 45% for women, compared to 38% for men 1. Women with obesity face an increased risk of serious health conditions, including Polycystic Ovary Syndrome (PCOS), uterine problems, infertility, breast and endometrial cancer. The "Reduce Size, Reduce Disease" campaign therefore aims not only to encourage behavioral change but also to dismantle the social stigma that treats obesity as a personal failure, fostering an understanding of it as a chronic disease that requires proper care.
Ms. Sunaiyanaa Kidkasetpaisal, Zuellig Pharma's General Manager for Commercialization in Thailand, said, "Zuellig Pharma is dedicated to enhancing the health of the Thai people by championing the understanding that obesity is not about aesthetics, and instead is a chronic disease requiring holistic treatment. We believe that equitable access to healthcare is the foundation of a sustainable society, and our 'Reduce Size, Reduce Disease' campaign is a direct reflection of this commitment, moving beyond promoting new treatment innovations to providing comprehensive knowledge and practical guidance on weight management. This seminar reflects our dedication in driving change and shifting the societal narrative on obesity from judgment to understanding and care, for the long-term health for everyone."
The "Obesity is a Disease" seminar involved healthcare practitioners from all over Thailand, who are committed to educating and deepening their understanding of obesity as a disease among Thais; and constantly find ways and solutions to help fight the disease.
Prof. Dr. Rungsima Wanitphakdeedecha, Head of the Department of Dermatology, Chief of the Division of Dermatologic Surgery, and Director of the Siriraj Skin Laser Center at the Faculty of Medicine Siriraj Hospital, Mahidol University, explained, "At its heart, the "Reduce Size, Reduce Disease" campaign is about inspiring people in Thailand to embrace a holistic approach to their well-being, focusing on safe and effective health management to prevent comorbidities linked to obesity. It shows that when we truly invest in our own well-being, long-term health will be sustainable."
Asst. Prof. Dr. Mart Maiprasert, Dean and Chairman of the Graduate Program Executive Committee at the College of Integrative Medicine (CIM), said "Effective weight management today hinges on multiple factors, including a strong partnership between patients and medical experts, proper lifestyle habits, good nutrition, and consistent exercise. Together, these elements form the foundation of what we call the 'X2' approach, which emphasizes that being healthy is not achieved through dieting or exercise alone but through a sustainable, balanced integration of both for lasting results."
Master Dr. Rassapoom Sumaetheiwit, a specialist in dermatology and aesthetic medicine, added, "Helping our clients with effective body composition management is not just a series of procedures, but an art grounded in medical science, demanding a deep, individual understanding of each patient to tailor the most appropriate and safe treatment plan. This integrated approach ensures that losing weight is not merely about aesthetics, but about achieving genuine health and physical balance. Our commitment is to provide this level of comprehensive, personalized care to deliver safe and sustainable long-term results."
The "Reduce Size, Reduce Disease" project aims to raise awareness that "Obesity is a disease" requiring medical attention, while also spotlighting the urgent public health challenge that obesity represents in Thailand.
About Zuellig Pharma
Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 17 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Korea Herald
2 days ago
- Korea Herald
Zuellig Pharma Launches "Obesity is a Disease" Seminar as Part of "Reduce Size, Reduce Disease" Campaign
The campaign aims to enhance the understanding of obesity as a chronic disease and solutions to help manage the disease among Thais and healthcare providers. BANGKOK, July 8, 2025 /PRNewswire/ -- Zuellig Pharma, a leading healthcare solutions provider in Asia, is organizing the "Obesity is a Disease" seminar as part of its "Reduce Size, Reduce Disease" awareness campaign. The seminar aims to reinforce the message that obesity is more than a cosmetic concern, and solutions to manage the disease among healthcare practitioners. It is a silent national public health crisis that significantly impacts individuals living with obesity, particularly women. Studies have highlighted the urgency of addressing rising obesity rates, as the 2014 National Health Examination Survey found that 37.5% of Thais aged 15 and over were obese (BMI > 25), with the rate for women at 41.8%. By 2023, this figure had climbed to 45% for women, compared to 38% for men 1. Women with obesity face an increased risk of serious health conditions, including Polycystic Ovary Syndrome (PCOS), uterine problems, infertility, breast and endometrial cancer. The "Reduce Size, Reduce Disease" campaign therefore aims not only to encourage behavioral change but also to dismantle the social stigma that treats obesity as a personal failure, fostering an understanding of it as a chronic disease that requires proper care. Ms. Sunaiyanaa Kidkasetpaisal, Zuellig Pharma's General Manager for Commercialization in Thailand, said, "Zuellig Pharma is dedicated to enhancing the health of the Thai people by championing the understanding that obesity is not about aesthetics, and instead is a chronic disease requiring holistic treatment. We believe that equitable access to healthcare is the foundation of a sustainable society, and our 'Reduce Size, Reduce Disease' campaign is a direct reflection of this commitment, moving beyond promoting new treatment innovations to providing comprehensive knowledge and practical guidance on weight management. This seminar reflects our dedication in driving change and shifting the societal narrative on obesity from judgment to understanding and care, for the long-term health for everyone." The "Obesity is a Disease" seminar involved healthcare practitioners from all over Thailand, who are committed to educating and deepening their understanding of obesity as a disease among Thais; and constantly find ways and solutions to help fight the disease. Prof. Dr. Rungsima Wanitphakdeedecha, Head of the Department of Dermatology, Chief of the Division of Dermatologic Surgery, and Director of the Siriraj Skin Laser Center at the Faculty of Medicine Siriraj Hospital, Mahidol University, explained, "At its heart, the "Reduce Size, Reduce Disease" campaign is about inspiring people in Thailand to embrace a holistic approach to their well-being, focusing on safe and effective health management to prevent comorbidities linked to obesity. It shows that when we truly invest in our own well-being, long-term health will be sustainable." Asst. Prof. Dr. Mart Maiprasert, Dean and Chairman of the Graduate Program Executive Committee at the College of Integrative Medicine (CIM), said "Effective weight management today hinges on multiple factors, including a strong partnership between patients and medical experts, proper lifestyle habits, good nutrition, and consistent exercise. Together, these elements form the foundation of what we call the 'X2' approach, which emphasizes that being healthy is not achieved through dieting or exercise alone but through a sustainable, balanced integration of both for lasting results." Master Dr. Rassapoom Sumaetheiwit, a specialist in dermatology and aesthetic medicine, added, "Helping our clients with effective body composition management is not just a series of procedures, but an art grounded in medical science, demanding a deep, individual understanding of each patient to tailor the most appropriate and safe treatment plan. This integrated approach ensures that losing weight is not merely about aesthetics, but about achieving genuine health and physical balance. Our commitment is to provide this level of comprehensive, personalized care to deliver safe and sustainable long-term results." The "Reduce Size, Reduce Disease" project aims to raise awareness that "Obesity is a disease" requiring medical attention, while also spotlighting the urgent public health challenge that obesity represents in Thailand. About Zuellig Pharma Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 17 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

Korea Herald
2 days ago
- Korea Herald
Johnson & Johnson Launches VARIPULSE™ Platform across Asia-Pacific, Advancing Atrial Fibrillation Treatment
The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency, reproducibility, and procedural accuracy. 1,i,ii,iii,iv,v,vi,vii,viii,ix The VARIPULSE™ Platform is approved in Japan, Hong Kong, China, Australia, Taiwan and Korea. IRVINE, Calif., July 8, 2025 /PRNewswire/ -- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced the launch of the VARIPULSE™ Platform in Asia-Pacific. The platform is used to perform catheter ablation procedures for atrial fibrillation (AFib), an irregular and often rapid heartbeat caused by extra, uncoordinated electrical signals in the atria. x AFib is associated with structural changes in the heart due to underlying conditions and lifestyle factors. x,xi It significantly increases the risk of stroke, heart failure, and mortality. The VARIPULSE™ Platform is the first PFA technology designed to streamline ablation and mapping through a single integrated workflow with the CARTO™ 3 System. This 3D electroanatomical cardiac mapping technology enables real-time visualization and supports precision, efficiency, reproducibility, and procedural accuracy for physicians treating patients with atrial fibrillation (AFib) xii. It enables safe and efficient i,ii,iii,iv,v,vi,vii, patient-centric therapy with minimal to no fluoroscopy exposurex iii,xiv,xv and is compatible with deep and/or conscious sedation. 2,xvi,xvii This innovation is backed by compelling clinical evidence. Both the inspIRE and admIRE clinical trials demonstrated strong safety and effectiveness of the VARIPULSE™ Platform: "The introduction of the VARIPULSE™ Platform in the Asia-Pacific region marks a significant advancement towards our goal of transforming atrial fibrillation care," stated Jing Li, Vice President, Electrophysiology & Neurovascular, Johnson & Johnson MedTech, Asia Pacific. "The adoption of the VARIPULSE™ Platform could demonstrate the unique value of integration with CARTO™ 3D to enhance efficiencies in the workflow of AFib treatment and improve patient outcomes." Atrial Fibrillation affects over 16 million people in Asia-Pacific xxi. Symptoms and clinical consequences of AFib disrupt patient's quality of life. The most common symptoms are heart palpitations, fatigue, shortness of breath, chest pain, and dizziness xxii. As a progressive condition, early intervention is critical to reducing the risk of stroke, heart failure, and cardiovascular mortality xxiii. Unlike traditional ablation methods that use heat or cold, PFA uses short bursts of energy to affect heart tissue, potentially reducing the risk of damage to surrounding tissue such as the esophagus, pulmonary veins, and phrenic nerve. "PFA, as a new type of energy, has the potential to further enhance the safety and efficacy of catheter ablation treatment, which is desirable for patients" said Dr. Yasuo Okumura 7, Professor and Department Head, Vice Hospital Director, Nihon University School of Medicine, Itabashi Hospital, Tokyo, Japan. "PFA is a relatively new medical technology, and therefore it is important to continue to assess its effectiveness and efficacy in Asia while ensuring proper use. But so far, we know that the integration of PFA technology with 3D mapping enables physicians to review their procedure in detail, and this contributes to quality of healthcare for patients." About the VARIPULSE™ Platform The VARIPULSE™ Platform is Johnson & Johnson MedTech's Pulsed Field ablation system. The fully integrated platform includes the VARIPULSE™ Catheter, TRUPULSE™ Generator, and CARTO™ 3 Mapping System VARIPULSE™ Software. The Platform is now approved for use in the United States, Europe, Asia Pacific, and Canada. Cardiovascular Solutions from Johnson & Johnson MedTech Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration, and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more about our MedTech sector's global scale and deep expertise in surgery, orthopaedics, vision, and cardiovascular solutions at Follow us at @JNJMedTech and on LinkedIn. Biosense Webster, Inc. is a Johnson & Johnson MedTech company. Cautions Concerning Forward-Looking Statements: This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the VARIPULSE™ Platform. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. © Johnson & Johnson and its affiliates 2025. All rights reserved. M_US_ELP_NAVI_403012

Korea Herald
2 days ago
- Korea Herald
Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma
Expanded indication makes SIR-Spheres ® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, Mass., July 7, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (FDA) approved SIR-Spheres ® Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma (HCC) in the United States. With this approval, SIR-Spheres ® is the only radioembolization therapy approved for the treatment of both metastatic colorectal cancer (mCRC) of the liver and HCC in the U.S. HCC is the most common form of liver cancer in adults in the U.S., according to the American Cancer Society. Radioembolization–commonly referred to as selective internal radiation therapy (SIRT)–with SIR-Spheres ® uses personalized dosimetry to deliver the optimal dose of radiation directly to tumors in patients with HCC. This approval gives clinicians expanded flexibility in selecting a liver-directed therapy that aligns with patient-specific needs and treatment goals. "The expanded indication makes SIR-Spheres ® the only Y-90 treatment approved in the U.S. for both HCC and mCRC," said Matt Schmidt, CEO of Sirtex. "This milestone reflects our ongoing commitment to delivering flexible, personalized therapies—with multiple dose options available daily—that empowers physicians to treat patients when and where it works best." This regulatory milestone is supported by results from the DOORwaY 90 study, a prospective, multicenter, open-label clinical trial evaluating the safety and efficacy of SIR-Spheres ® in treating HCC. The study enrolled 100 patients across 18 U.S. centers, with 65 patients included in the interim primary efficacy cohort. DOORwaY 90 met its prespecified co-primary endpoints, demonstrating a best overall response rate (ORR) of 98.5% as assessed by independent central review. All evaluable patients demonstrated a response, indicating a 100% local tumor control rate. Additionally, the median duration of response (DoR) exceeded 300 days. These findings highlight SIR-Spheres ® as a highly effective liver-directed therapy with a favorable safety profile. "This study moves the field of radioembolization forward with reproducible dosimetry outcomes and a strong safety profile linked to very positive clinical results," said Dr. Armeen Mahvash, Interventional Radiologist at MD Anderson Cancer Center and Co-Principal Investigator of the DOORwaY 90 Study. "This will give multidisciplinary care teams the confidence to recommend SIR-Spheres ® for HCC treatment." For more information and details on how to incorporate SIR-Spheres ® into your practice, please contact Sirtex at info-use@ About SIR-Spheres ® SIR-Spheres ® Y-90 resin microspheres are indicated for the local tumor control of unresectable hepatocellular carcinoma (HCC) in patients with no macrovascular invasion, Child-Pugh A cirrhosis, well-compensated liver function, and good performance status. They are also indicated for the treatment of unresectable metastatic liver tumors from primary colorectal cancer with adjuvant intra-hepatic artery chemotherapy (IHAC) of FUDR (Floxuridine). Caution: Federal (USA) law restricts this device for sale by or on the order of a physician. Consult the Instructions for Use ( for a complete listing of indications, contraindications, side effects, warnings and precautions. About Sirtex Sirtex Medical is a global healthcare company focused on advancing minimally invasive, liver-directed cancer and embolization therapies. With offices in the U.S., Australia, Europe, and Asia, Sirtex delivers innovative interventional oncology and embolization solutions to physicians and patients worldwide. The company's lead product, SIR-Spheres ® Y-90 resin microspheres, is now the only FDA approved product in the United States indicated for both the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC). For more information, visit